Research Interests
Advancing the understanding of human immunodeficiency syndromes through genetic sequencing and the development of animal models. Ultimate aim to provide strategies for early surveillance of disease associated complications including the development of hematologic malignancies and novel therapeutics aimed at correcting the immune dysregulation
Selected Grants
R01: Genetic Origins of Adverse Outcomes in African Americans with Lymphoma
ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2028Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) - Cost Reimbursable
Clinical TrialPrincipal Investigator · Awarded by Cincinnati Children's Hospital Medical Center · 2021 - 2024HAErmony1: A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING
Clinical TrialPrincipal Investigator · Awarded by BioMarin Pharmaceutical, Inc. · 2022 - 2024HAE Outcome Study. An observational, non-interventional, study of patients with Hereditary Angioedema in the United States and Canada.
Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceutical Company Limited · 2019 - 2024BluePrint Medicines KIT D816V BLU-SM-1101 Evalute the prevalence of the KIT D816V mutation i peripheral blood of patients with evidence of systemic mast cell activation
Clinical TrialPrincipal Investigator · Awarded by Blueprint Medicines Corporation · 2022 - 2024Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD)- Fixed Price
Clinical TrialPrincipal Investigator · Awarded by Cincinnati Children's Hospital Medical Center · 2023 - 2023BCX7353-204 An open label study to evaluate the long-term safety of daily oral BCS7353 in subjects with Type I and II hereditary angioedema
Clinical TrialPrincipal Investigator · Awarded by Biocryst Corporation · 2019 - 2023Understanding the context-dependent roles of mutations in lymphoma
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2021Clinical indicators for early bone loss in Common Variable Immunodeficiency
ResearchPrincipal Investigator · Awarded by Immune Deficiency Foundation · 2019 - 2020IgPro20_1001 Phase I, Comparison of 2 infusion devisces with respet to Pharmacokinetics, safety, and tolerability of Hizentra: an investigational wearable infusor and Crono S-PID-50 Infusion Pump
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2018 - 2020HELP Study Extension: An open-label study to evaluate the long-term safety and efficacy of DX-2930 for prevention against acute attacks of hereditary angioedema (HAE)
Clinical TrialPrincipal Investigator · Awarded by Dyax Corporation · 2017 - 2020CSL Behring IgPro20_4004
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2017 - 2019BCX7353-302:Phase 3 randomized doubleblind placebo controlled parallel group study evaluate efficacy&safety of 2-dose levels BCS7353 as oral treatment for prevention of attacks w/hereditary angioedema
Clinical TrialPrincipal Investigator · Awarded by Biocryst Corporation · 2018 - 2019The HELP Study
Clinical TrialPrincipal Investigator · Awarded by Dyax Corporation · 2016 - 2017The genetics of hepatosplenic T cell lymphoma
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2017Clinical Oncology Research Career Development Program
ResearchResearch Candidate · Awarded by National Institutes of Health · 2009 - 2015External Relationships
- Blueprint Medicines
- CSL
- Data Driven Bioscience
- Grifols
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.